{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:08:06Z","timestamp":1760188086723},"reference-count":36,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We determined the prognostic importance of morphologically identifiable persistent disease at day 15 and days 22 to 25 of remission induction in childhood acute lymphoblastic leukemia (ALL). Among 546 patients entered on 2 consecutive protocols, 397 patients had evaluable bone marrow (BM) examinations on day 15 (\u00b1\u20091 day) and 218 on days 22 to 25 (\u00b1\u20091 day). Fifty-seven patients (14%) had persistent lymphoblasts (\u2265\u20091%) in the BM on day 15 and 27 patients (5.5%) had persistent lymphoblasts on days 22 to 25. The 5-year event-free survival (EFS) was significantly worse for patients with lymphoblasts on day 15 (40%\u2009\u00b1\u20096%) or on days 22 to 25 (4%\u2009\u00b1\u20093%) as compared to those without lymphoblasts on these dates (78%\u2009\u00b1\u20092% and 76%\u2009\u00b1\u20092%, respectively, P\u2009&amp;lt;\u2009.001 for both comparisons). A worse prognosis was observed even for patients with a low percentage of lymphoblasts (ie, 1%-4%) at either day 15 (5-year EFS\u2009=\u200956%\u2009\u00b1\u20098%) or days 22 to 25 (5-year EFS\u2009=\u20090%) compared to those without morphologically identifiable persistent lymphoblasts at these times (P\u2009&amp;lt;\u2009.001 for both comparisons). The prognostic impact of persistent lymphoblasts on both dates remained significant after adjusting for other known risk factors, including treatment protocol, age, white blood cell count, DNA index, cell lineage, and central nervous system status, and National Cancer Institute\/Rome criteria simultaneously. Hence, persistence of lymphoblasts (even 1%-4%) on day 15 of remission induction was associated with a poor prognosis and on days 22 to 25 signified a particularly dismal outcome; these very high-risk patients require novel or more intensive therapy to improve outcome.<\/jats:p>","DOI":"10.1182\/blood.v100.1.43","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:48:18Z","timestamp":1033508898000},"page":"43-47","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"100","author":[{"given":"John T.","family":"Sandlund","sequence":"first","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Harrison","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Rivera","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick G.","family":"Behm","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Head","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Boyett","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Rubnitz","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Raimondi","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Hudson","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Relling","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Evans","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"From the Departments of Hematology-Oncology, Pathology and Laboratory Medicine, Biostatistics and Epidemiology, and Pharmaceutical Sciences, St Jude Children's Research Hospital, and the University of Tennessee, College of Medicine, Memphis, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021221473331400_B1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199808273390907","article-title":"Acute lymphoblastic leukemia.","volume":"339","author":"Pui","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021221473331400_B2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199310283291801","article-title":"Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital.","volume":"329","author":"Rivera","year":"1993","journal-title":"N Engl J Med."},{"key":"2020021221473331400_B3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood.V76.8.1449.1449","article-title":"Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.","volume":"76","author":"Pui","year":"1990","journal-title":"Blood."},{"key":"2020021221473331400_B4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V82.2.343.343","article-title":"Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia.","volume":"82","author":"Pui","year":"1993","journal-title":"Blood."},{"key":"2020021221473331400_B5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.1992.10.4.606","article-title":"Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study.","volume":"10","author":"Trueworthy","year":"1992","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10428199209049820","article-title":"Extremely poor prognosis of pediatric acute lymphoblastic leukemia with translocation (9;22): updated experience.","volume":"8","author":"Fletcher","year":"1992","journal-title":"Leuk Lymphoma."},{"key":"2020021221473331400_B7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood.V81.9.2386.2386","article-title":"Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome.","volume":"81","author":"Chen","year":"1993","journal-title":"Blood."},{"key":"2020021221473331400_B8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1994.12.5.909","article-title":"11q23\/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.","volume":"12","author":"Pui","year":"1994","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood.V77.3.440.440","article-title":"Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases.","volume":"77","author":"Pui","year":"1991","journal-title":"Blood."},{"key":"2020021221473331400_B10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM199309233291302","article-title":"Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.","volume":"329","author":"Thirman","year":"1993","journal-title":"N Engl J Med."},{"key":"2020021221473331400_B11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V76.1.117.117","article-title":"Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23\u2013p13): a Pediatric Oncology Group study.","volume":"76","author":"Crist","year":"1990","journal-title":"Blood."},{"key":"2020021221473331400_B12","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.1990.8.8.1380","article-title":"Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19).","volume":"8","author":"Raimondi","year":"1990","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B13","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.1994.12.12.2601","article-title":"Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1:19)(q23\u2013p13) or its derivative.","volume":"12","author":"Pui","year":"1994","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B14","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V85.12.3662.bloodjournal85123662","article-title":"The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.","volume":"85","author":"Romana","year":"1995","journal-title":"Blood."},{"key":"2020021221473331400_B15","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1182\/blood.V86.11.4263.bloodjournal86114263","article-title":"High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia.","volume":"86","author":"Romama","year":"1995","journal-title":"Blood."},{"key":"2020021221473331400_B16","first-page":"1985","article-title":"TEL\/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.","volume":"9","author":"Shurtleff","year":"1995","journal-title":"Leukemia."},{"key":"2020021221473331400_B17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1200\/JCO.1997.15.3.1150","article-title":"TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance.","volume":"15","author":"Rubnitz","year":"1997","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V89.4.1143","article-title":"Case- control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study.","volume":"89","author":"Rubnitz","year":"1997","journal-title":"Blood."},{"key":"2020021221473331400_B19","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1182\/blood.V88.11.4252.bloodjournal88114252","article-title":"TEL\/AML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.","volume":"88","author":"McLean","year":"1996","journal-title":"Blood."},{"key":"2020021221473331400_B20","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1182\/blood.V87.7.2870.bloodjournal8772870","article-title":"Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age.","volume":"87","author":"Behm","year":"1996","journal-title":"Blood."},{"key":"2020021221473331400_B21","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/1097-0142(19950401)75:7<1684::AID-CNCR2820750720>3.0.CO;2-2","article-title":"Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia.","volume":"75","author":"Arico","year":"1995","journal-title":"Cancer."},{"key":"2020021221473331400_B22","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.1989.7.12.1807","article-title":"Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group.","volume":"7","author":"Miller","year":"1989","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mpo.2950180403","article-title":"Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.","volume":"18","author":"Gaynon","year":"1990","journal-title":"Med Pediatr Oncol."},{"key":"2020021221473331400_B24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1096-911X(199707)29:1<16::AID-MPO3>3.0.CO;2-V","article-title":"Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.","volume":"29","author":"Schultz","year":"1997","journal-title":"Med Pediatr Oncol."},{"key":"2020021221473331400_B25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/(SICI)1096-911X(199712)29:6<541::AID-MPO4>3.0.CO;2-K","article-title":"Comparison of the cellularity and presence of residual leukemia in bone marrow aspirate and biopsy specimens in pediatric patients with acute lymphoblastic leukemia (ALL) at day 7-14 of chemotherapy.","volume":"29","author":"Kidd","year":"1997","journal-title":"Med Pediatr Oncol."},{"key":"2020021221473331400_B26","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86.","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood."},{"key":"2020021221473331400_B27","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood.V86.4.1292.bloodjournal8641292","article-title":"Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia.","volume":"86","author":"Gajjar","year":"1995","journal-title":"Blood."},{"key":"2020021221473331400_B28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1996.14.2.389","article-title":"Cytoreduction and prognosis in acute lymphoblastic leukemia\u2014the importance of early marrow response: report from the Children's Cancer Group.","volume":"14","author":"Steinherz","year":"1996","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B29","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B","article-title":"Early response to therapy and outcome in childhood acute lymphoblastic leukemia.","volume":"80","author":"Gaynon","year":"1997","journal-title":"Cancer."},{"key":"2020021221473331400_B30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0140-6736(91)90733-6","article-title":"Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy.","volume":"337","author":"Rivera","year":"1991","journal-title":"Lancet."},{"key":"2020021221473331400_B31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional versus individualized chemotherapy for childhood acute lymphoblastic leukemia.","volume":"338","author":"Evans","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021221473331400_B32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021221473331400_B33","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst."},{"key":"2020021221473331400_B34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4899-3115-3","volume-title":"Modelling Survival Data in Medical Research.","author":"Collett","year":"1994"},{"key":"2020021221473331400_B35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1993.11.3.527","article-title":"Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial.","volume":"11","author":"Tubergun","year":"1993","journal-title":"J Clin Oncol."},{"key":"2020021221473331400_B36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)10295-1","article-title":"Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia.","volume":"351","author":"Coustan-Smith","year":"1998","journal-title":"Lancet."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/1\/43\/1683633\/h81302000043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/1\/43\/1683633\/h81302000043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:54:24Z","timestamp":1581562464000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/1\/43\/133955\/Persistence-of-lymphoblasts-in-bone-marrow-on-day"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v100.1.43","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7,1]]}}}